RGDXQ (Response Genetics) Gross Margin %: 0.00% (As of Dec. 2015)


What is Response Genetics Gross Margin %?

Response Genetics RGDXQ -98.00% Gross Margin % is 0.00% as of Dec. 2015.

Gross Margin % is calculated as gross profit divided by its revenue. Response Genetics's Gross Profit for the three months ended in Dec. 2015 was $0.00 Mil. Response Genetics's Revenue for the three months ended in Dec. 2015 was $0.00 Mil. Therefore, Response Genetics's Gross Margin % for the quarter that ended in Dec. 2015 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Response Genetics's Gross Margin % or its related term are showing as below:


RGDXQ's Gross Margin % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 51.14
* Ranked among companies with meaningful Gross Margin % only.

Response Genetics had a gross margin of N/A% for the quarter that ended in Dec. 2015 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Response Genetics was 0.00% per year.


Response Genetics  (OTCPK:RGDXQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Response Genetics had a gross margin of N/A% for the quarter that ended in Dec. 2015 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Response Genetics Gross Margin % Related Terms


Response Genetics Gross Margin % Historical Data

* Premium members only.

The historical data trend for Response Genetics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Gross Margin % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.18 44.41 25.49 17.12 21.85

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.59 43.05 136.28 38.93 0.00

RGDXQ vs PSID, GBSN, ETAH: Gross Margin % Comparison

For the Diagnostics & Research subindustry, Response Genetics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Response Genetics Gross Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Response Genetics's Gross Margin % falls into.



Response Genetics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Response Genetics's Gross Margin for the fiscal year that ended in Dec. 2015 is calculated as

Gross Margin % (A: Dec. 2015 )=Gross Profit (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=3.9 / 18.04
=(Revenue - Cost of Goods Sold) / Revenue
=(18.04 - 14.098) / 18.04
=21.85 %

Response Genetics's Gross Margin for the quarter that ended in Dec. 2015 is calculated as


Gross Margin % (Q: Dec. 2015 )=Gross Profit (Q: Dec. 2015 ) / Revenue (Q: Dec. 2015 )
=0 / 0
=(Revenue - Cost of Goods Sold) / Revenue
=(0 - 0) / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
Response Genetics (RGDXQ) has a Gross Margin % of 0.00% as of Dec. 2015. Gross margin is the ratio of total gross profit to net sales. View historical data on Response Genetics and its competitors.
Is Response Genetics' Gross Margin % too high?
Response Genetics' current Gross Margin % is 0.00%.
How does Response Genetics' Gross Margin % compare to PSID and GBSN?
Response Genetics' Gross Margin % of 0.00% can be compared against companies in the Medical Diagnostics & Research industry. The industry median Gross Margin % is 51.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Response Genetics and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Response Genetics's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Gross Margin % is 0.00% as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.